Home › NDC Lookup › RxCUI directory › RxCUI 1605455

{4 (apremilast 10 MG Oral Tablet [Otezla]) / 4 (apremilast 20 MG Oral Tablet [Otezla]) / 4... — RxCUI 1605455

RxNorm drug concept · Brand name pack
RxCUI 1605455 Brand name pack · BPCK ● Current RxNorm concept 8 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1605455
Official name{4 (apremilast 10 MG Oral Tablet [Otezla]) / 4 (apremilast 20 MG Oral Tablet [Otezla]) / 47 (apremilast 30 MG Oral Tablet [Otezla]) } Pack [Otezla 28-Day 10/20/30 Starter Pack]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known asOtezla 28-Day 10/20/30 Starter Pack
FDA products mapped8
Package NDCs mapped9
Reported Medicaid activity (SDUD)68,281 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Apremilast: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats psoriatic arthritis, plaque psoriasis, and oral ulcers from Behçet's Disease in adults. Children 6 and older can use it for psoriatic arthritis and moderate to severe pla...
  • Take it by mouth, with or without food, and swallow the tablet whole. Otezla starts with a 5-day build-up to ease stomach side effects. Follow your prescriber's directions.
  • Diarrhea, nausea, headache, and cold-like symptoms are most common. They often show up in the first weeks and tend to improve. Call your doctor if diarrhea, nausea or vomiting is s...
  • Yes. Apremilast is linked to more depression, and weight loss can occur. Tell your doctor about mood changes or weight loss you can't explain.
📖 Read our full Apremilast guide →

🕸️ Concept Web — How {4 (apremilast 10 MG Oral Tablet [Otezla]) / 4 (... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {4 (apremilast 10 MG Oral Tablet [Otezla]) / 4 (apremilast 20 MG Oral Tablet [Otezla]) / 47 (apremilast 30 MG Oral Tablet [Otezla]) } Pack [Otezla 28-Day 10/20/30 Starter Pack] RxCUI 1605455

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Apremilast 1492727
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Otezla 1492733
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Apremilast Oral Tablet 1492731
    • Apremilast Oral Product 1492729
    • Apremilast Pill 1492730
    • Apremilast Oral Tablet [Otezla] 1492735
    • Otezla Oral Product 1492736
    • Otezla Pill 1492737
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 12

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 24 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

8 products · 9 package NDCs
9 package NDCs map to RxCUI 1605455 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55513-0137-60 60 TABLET, FILM COATED in 1 BOTTLE (55513-137-60) Otezla Amgen, Inc 2020-02-26
55513-0137-95 1 BLISTER PACK in 1 CARTON (55513-137-95) / 28 TABLET, FILM... Otezla Amgen, Inc 2020-02-26
55513-0369-55 1 BLISTER PACK in 1 CARTON (55513-369-55) / 1 KIT in 1 BLIS... Otezla Amgen, Inc 2020-02-26
55513-0485-96 5 BLISTER PACK in 1 CARTON (55513-485-96) / 1 KIT in 1 BLIS... Otezla Amgen, Inc 2020-02-26
55513-0497-60 60 TABLET, FILM COATED in 1 BOTTLE (55513-497-60) Otezla Amgen, Inc 2024-04-27
55513-0508-55 1 KIT in 1 BLISTER PACK (55513-508-55) * 51 TABLET, FILM C... Otezla Amgen, Inc 2024-04-27
55513-0516-41 1 BLISTER PACK in 1 CARTON (55513-516-41) / 1 KIT in 1 BLIS... Otezla Amgen, Inc 2020-02-26
55513-0519-30 30 TABLET, FILM COATED in 1 BOTTLE (55513-519-30) Otezla Amgen, Inc 2025-08-31
55513-0996-95 3 BLISTER PACK in 1 CARTON (55513-996-95) / 1 KIT in 1 BLIS... Otezla Amgen, Inc 2024-04-27
Observed labelers: Amgen, Inc (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.